Increased Incidence of New-Onset Diabetes Mellitus Type II Following Haploidentical Bone Marrow Transplant with Post-Transplant Cyclophosphamide for Sickle Cell DiseaseDilan A. Patel, Adetola A. Kassim, Josu de la Fuente et al.|Blood|2020Cited by 0
ABO Incompatibility Did Not Impact Outcomes after Haploidentical Bone Marrow Transplantation with Posttransplant Cyclophosphamide for Patients with Sickle Cell Disease: Single Center ExperienceDanielle Murphy, Adetola A. Kassim, Phavina A Akhom et al.|Transplantation and Cellular Therapy|2023Cited by 0